Taysha’s piv­otal tri­al plans; Keros to stop work on PAH drug, lay off 45% of staff

Plus, news about Im­mu­nic, Neu­ro­crine Bio­sciences, Al­con, Aus­per­Bio and Evom­mune:

Taysha Gene Ther­a­pies re­veals plans for piv­otal tri­al, $200M of­fer­ing: The biotech on Wednes­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER